Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: Implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections

FEMS Immunology and Medical Microbiology

Volumn 61, Issue 2, 2011, Pages 141-146

  Tsivkovskii, Ruslan ^a   Sabet, Mojgan ^a   Tarazi, Ziad ^a   Griffith, David C ^a   Lomovskaya, Olga ^a   Dudley, Michael N ^a  

^a Mpex Pharmaceuticals Inc   (United States)

Author keywords

Airway; Antimicrobial agents; Cystic fibrosis; Inflammation; Levofloxacin

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LEVOFLOXACIN; MESSENGER RNA; MP 376; TOBRAMYCIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFECT; DRUG FORMULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CHRONIC DISEASE; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; OFLOXACIN; PNEUMONIA; TOBRAMYCIN;

EID: 79951480062     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00755.x     Document Type: Article

References (20)

1. Araujo F, Slifer T, Li S, Kuver A, Fong L & Remington J (2004) Gemifloxacin inhibits cytokine secretion by lipopolysaccharide stimulated human monocytes at the post-transcriptional level. Clin Microbiol Infec 10: 213-219.
2. Araujo FG, Slifer TL & Remington JS (2002) Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin Microbiol Infec 8: 26-30.
3. Blau H, Klein K, Shalit I, Halperin D & Fabian I (2007) Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol-Lung C 292: L343-L352.
4. Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH & Shin WS (2003) Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Ch 47: 3704-3707.
5. Dalhoff A (2005) Immunomodulatory activities of fluoroquinolones. Infection 33 (suppl 2): 55-70.
6. Dalhoff A & Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359-371.
7. Donnarumma G, Paoletti I, Buommino E, Iovene MR, Tudisco L, Cozza V & Tufano MA (2007) Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide. Peptides 28: 2286-2292.
8. Elizur A, Cannon CL & Ferkol TW (2008) Airway inflammation in cystic fibrosis. Chest 133: 489-495.
9. Flume PA, O'Sullivan BP, Robinson KA et al. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Resp Crit Care Med 176: 957-969.
10. Griffith D, Rock J, Hansen C, Pressler T, Balchen T, Jensen T, Surber M, Bostian K & Dudley M (2007) Pharmacokinetics and safety of MP-376 (levofloxacin solution for inhalation) in normal healthy volunteers and cystic fibrosis patients. Pediatr Pulm 42 (suppl 30): 303.
11. Hashimoto S, Matsumoto K, Gon Y, Maruoka S, Hayashi S, Asai Y, Machino T & Horie T (2000) Grepafloxacin inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in human airway epithelial cells. Life Sci 66: PL 77-PL 82.
12. Jacquot J, Tabary O, Le Rouzic P & Clement A (2008) Airway epithelial cell inflammatory signalling in cystic fibrosis. 40: 1703-1715.
13. Khan AA, Slifer TR & Remington JS (1998) Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Ch 42: 1713-1717.
14. Kitazawa T, Nakayama K, Okugawa S, Koike K, Shibasaki Y & Ota Y (2007) Biphasic regulation of levofloxacin on lipopolysaccharide-induced IL-1beta production. Life Sci 80: 1572-1577.
15. Ono Y, Ohmoto Y, Ono K, Sakata Y & Murata K (2000) Effect of grepafloxacin on cytokine production in vitro. J Antimicrob Chemoth 46: 91-94.
16. Shalit I, Halperin D, Haite D, Levitov A, Romano J, Osherov N & Fabian I (2006) Anti-inflammatory effects of moxifloxacin on IL-8, IL-1beta and TNF-alpha secretion and NFkappaB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimicrob Chemoth 57: 230-235.
17. Strieter RM (2002) Interleukin-8: a very important chemokine of the human airway epithelium. Am J Physiol-Lung C 283: L688-L689.
18. Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A & Fabian I (2004) Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Ch 48: 1974-1982.
19. Yoshimura T, Kurita C, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F & Nagai H (1996) Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells. Chemotherapy 42: 459-464.
20. Zimmermann GS, Neurohr C, Villena-Hermoza H, Hatz R & Behr J (2009) Anti-inflammatory effects of antibacterials on human bronchial epithelial cells. Respir Res 10: 89.